FDMT (4D Molecular Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by FDMT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2026-08-21 | David Kirn | See Remarks | MIXED | — | — |
| 2026-08-17 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2026-08-05 | David Kirn | See Remarks | Sell | — | — |
| 2026-08-04 | David Kirn | See Remarks | Sell | — | — |
| 2026-07-14 | David Kirn | See Remarks | Sell | — | — |
| 2026-07-02 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2026-06-25 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2026-06-23 | David Kirn | See Remarks | Sell | — | — |
| 2026-06-18 | SUSANNAH GRAY | Director | A | — | — |
| 2026-06-18 | GLENN SBLENDORIO | Director | A | — | — |
| 2026-06-18 | JOHN F MILLIGAN | Director | A | — | — |
| 2026-06-18 | Shawn Tomasello | Director | A | — | — |
| 2026-06-18 | CHARLES THEUER | Director | A | — | — |
| 2026-06-18 | Jacob Chacko | Director | A | — | — |
| 2026-06-18 | Nancy Miller-Rich | Director | A | — | — |
| 2026-06-02 | David Kirn | See Remarks | Sell | — | — |
| 2026-03-27 | Scott Bizily | Chief Legal Officer | A | — | — |
| 2026-03-27 | David Kirn | Chief Executive Officer | A | — | — |
| 2026-03-27 | Christopher Paul Simms | See Remarks | A | — | — |
| 2026-03-24 | Ashoo Gupta | VP, Finance and Controller | MIXED | — | — |
| 2026-01-07 | GLENN SBLENDORIO | Director | A | — | — |
| 2025-12-23 | Ashoo Gupta | VP, Finance and Controller | MIXED | — | — |
| 2025-12-19 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2025-12-16 | CHARLES THEUER | Director | M | — | — |
| 2025-12-11 | Kristian Humer | Chief Financial Officer | A | — | — |
| 2025-11-19 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2025-10-27 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2025-10-20 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2025-10-14 | Scott Bizily | Chief Legal Officer | Sell | — | — |
| 2025-09-26 | Scott Bizily | Chief Legal Officer | Sell | — | — |
| 2025-06-20 | Nancy Miller-Rich | Director | A | — | — |
| 2025-06-20 | Jacob Chacko | Director | A | — | — |
| 2025-06-20 | CHARLES THEUER | Director | A | — | — |
| 2025-06-20 | SUSANNAH GRAY | Director | A | — | — |
| 2025-06-20 | Shawn Tomasello | Director | A | — | — |
| 2025-06-20 | JOHN F MILLIGAN | Director | A | — | — |
| 2025-03-10 | Scott Bizily | Chief Legal Officer | A | — | — |
| 2025-03-10 | Robert Young Kim | Chief Medical Officer | A | — | — |
| 2025-03-10 | David Kirn | Chief Executive Officer | A | — | — |
| 2025-03-10 | Fariborz Kamal | President & COO | A | — | — |
| 2025-03-10 | Uneek Mehra | See Remarks | A | — | — |
| 2024-12-10 | RA Capital Healthcare Fund LP | 10%+ Owner | J | — | — |
| 2024-11-13 | BVF I GP LLC | — | J | — | — |
| 2024-09-18 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2024-08-21 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2024-07-18 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2024-07-15 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| 2024-07-12 | David Kirn | Chief Executive Officer | MIXED | — | — |
| 2024-07-03 | Scott Bizily | Chief Legal Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,787,914 | — |
| — | 10%+ Owner | 4,563,211 | — |
| — | 10%+ Owner | 4,247,914 | — |
| — | 10%+ Owner | 3,937,914 | — |
| — | See Remarks | 1,494,895 | — |
| — | Director | 925,935 | — |
| — | Director | 458,190 | — |
| — | Director | 100,000 | — |
| — | — | 87,911 | — |
| — | VP, Finance and Controller | 46,914 | — |
| — | Director | 41,684 | — |
| — | Chief Financial Officer | 11,045 | — |
| — | Chief Legal Officer | 9,201 | — |
| — | Chief Medical Officer | 7,595 | — |
| — | President & COO | 4,347 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FDMT quote page; the site-wide leaderboard is on the insider transactions hub.